Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
177Lu-LNC1003
/
Dongcheng Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
177Lu-LNC1003
/
Dongcheng Pharma
New trial, Metastases:
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
(clinicaltrials.gov) - Nov 14, 2022
P=N/A
, N=9, Recruiting,
Sponsor: Peking Union Medical College Hospital